
Opinion|Videos|January 15, 2025
Additional Safety Considerations With PBC Treatments
Panelists discuss how managing primary biliary cholangitis (PBC) in women of childbearing age requires careful consideration of pregnancy risk categories for different medications, with UDCA being the safest option during pregnancy, while second-line therapies require strict contraception and careful monitoring of hormone interactions to ensure optimal safety and efficacy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How should clinicians approach fetal toxicity risks with PBC treatments, especially when managing women of childbearing age, and what precautions are recommended?
- Explain the relevance of the interaction between PBC therapies and hormone replacement therapy. How should these interactions be managed to ensure patient safety?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FAQ: Guidance for Pharmacists, SSRIs Under Scrutiny and Political Debate
2
What Pharmacists Should Know About High-Dose Semaglutide’s Safety Profile
3
Ensitrelvir Demonstrates Significant COVID-19 Post-Exposure Prophylaxis Efficacy in Phase 3 Trial
4
A First-of-Its-Kind All-Oral Option Receives FDA Approval for Newly Diagnosed AML
5


































































































































